Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD108
- Development stage
- Phase 1
- Lead developer
- AIDEA PHARMA
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
AD108 is an innovative small molecule neuroprotective agent being developed by Jiangsu Aidi Pharmaceutical (also known as Aidea Pharma) for the treatment of acute ischemic stroke. As a Class 1 innovative drug in China, it is designed to mitigate the neuronal damage that occurs during the ischemic cascade following a stroke event, with the objective of improving neurological functional recovery and reducing long-term disability. The compound is currently in Phase 1 clinical development, where its safety, tolerability, and pharmacokinetic profile are being evaluated in human subjects.
Beyond the preview
Go deeper on AD108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD108.